Moreover, BAX-mutated CH has been shown to arise after the treatment with a BCL-2 inhibitor, venetoclax, in patients with chronic lymphocytic leukemia (CLL) (89), strongly reflecting the evolutionary dynamics in response to targeting antiapoptotic proteins. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.